Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Indaptus Therapeutics Inc (INDP)

Indaptus Therapeutics Inc (INDP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,568
  • Shares Outstanding, K 2,101
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,020 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -8.96
  • Growth Rate Est. (year over year) +11,249.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.92 +47.39%
on 12/23/25
3.66 -22.54%
on 01/16/26
+0.81 (+39.66%)
since 12/22/25
3-Month
1.65 +71.82%
on 11/21/25
3.76 -24.52%
on 10/27/25
-0.62 (-17.83%)
since 10/22/25
52-Week
1.65 +71.82%
on 11/21/25
47.60 -94.04%
on 03/18/25
-23.76 (-89.34%)
since 01/22/25

Most Recent Stories

More News
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative...

INDP : 2.83 (+6.80%)
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative...

INDP : 2.83 (+6.80%)
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative...

INDP : 2.83 (+6.80%)
Indaptus Therapeutics Provides Clinical Update

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent...

INDP : 2.83 (+6.80%)
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C....

INDP : 2.83 (+6.80%)
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative...

INDP : 2.83 (+6.80%)
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

INDP : 2.83 (+6.80%)
Indaptus Therapeutics Announces Reverse Stock Split

INDP : 2.83 (+6.80%)
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

/CNW/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going...

ONCY : 1.2594 (+7.64%)
AUTL : 1.5350 (+4.42%)
INDP : 2.83 (+6.80%)
SLS : 4.57 (-0.22%)
ONC.TO : 1.42 (+2.16%)
CATX : 2.70 (+5.88%)
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INDP),(NYSE:CATX),(NASDAQ:SLS),(NASDAQ:AUTL EQNX::TICKER_END

ONCY : 1.2594 (+7.64%)
AUTL : 1.5350 (+4.42%)
INDP : 2.83 (+6.80%)
SLS : 4.57 (-0.22%)
ONC.TO : 1.42 (+2.16%)
CATX : 2.70 (+5.88%)

Business Summary

Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec...

See More

Key Turning Points

3rd Resistance Point 3.28
2nd Resistance Point 3.13
1st Resistance Point 2.89
Last Price 2.83
1st Support Level 2.51
2nd Support Level 2.36
3rd Support Level 2.12

See More

52-Week High 47.60
Fibonacci 61.8% 30.05
Fibonacci 50% 24.63
Fibonacci 38.2% 19.20
Last Price 2.83
52-Week Low 1.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar